目的 探討瀝水調(diào)脂膠囊聯(lián)合瑞舒伐他汀鈣片治療兒童高脂血癥的臨床療效。方法 選取2019年2月-2020年11月開封市兒童醫(yī)院收治的132例高脂血癥患兒作為研究對象，對所有患兒根據(jù)隨機(jī)數(shù)字表法分為對照組和治療組，每組各66例。對照組口服瑞舒伐他汀鈣片，10 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服瀝水調(diào)脂膠囊，3粒/次，3次/d。兩組連續(xù)治療8周。觀察兩組的治療效果，比較兩組患兒的血脂指標(biāo)、載脂蛋白和血清炎癥因子水平。結(jié)果 治療后，治療組的總有效率為90.91%，對照組的總有效率為77.27%，組間比較有明顯差異（P<0.05）。治療后，兩組的總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）、TC-HDL-C/高密度脂蛋白膽固醇（HDL-C）均顯著降低（P<0.05），以治療組TC、TG、LDL-C、TC-HDL-C/HDL-C降低更明顯（P<0.05）。治療后，兩組的載脂蛋白AI（ApoAI）、載脂蛋白B（ApoB）、ApoB/ApoAI明顯下降，差異有統(tǒng)計學(xué)意義（P<0.05）；治療組的ApoAI、ApoB、ApoB/ApoAI比對照組低，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的C反應(yīng)蛋白（CRP）、白細(xì)胞介素-6（IL-6）、細(xì)胞間黏附分子-1（ICAM-1）水平顯著降低，差異有統(tǒng)計學(xué)意義（P<0.05）；治療后治療組的CRP、IL-6、ICAM-1水平比對照組低，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 瀝水調(diào)脂膠囊聯(lián)合瑞舒伐他汀鈣片治療小兒高脂血癥的療效確切，可調(diào)節(jié)載脂蛋白，降低血脂水平和炎癥反應(yīng)，且藥物安全性良好。

Objective To investigate the clinical efficacy of Lishui Tiaozhi Capsules combined with Rosuvastatin Calcium Tablets in treatment of hyperlipidemia in children. Methods Children (122 cases) with hyperlipidemia in Kaifeng Children's Hospital from February 2019 to February 2020 were divided into control and treatment groups according to the random number table method, and each group had 66 cases. Children in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Children in the treatment group were po administered with Lishui Tiaozhi Capsules on the basis of the control group, 3 grains/time, three times daily. Children in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the blood lipid index, apolipoprotein, and serum inflammatory index in two groups were compared. Results After treatment, the total effective rate was 90.91% in the treatment group, and 77.27% in the control group, and there was significant difference between two groups (P<0.05). After treatment, the TC, TG, LDL-C, and TC-HDL-C/HDL-C in two groups were significantly decreased (P<0.05), and the TC, TG, LDL-C, and TC-HDL-C/HDL-C in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the ApoAI, ApoB, and ApoB/ApoAI of two groups were significantly decreased (P<0.05). The ApoAI, ApoB, and ApoB/ApoAI in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of the CRP, IL-6, and ICAM-1 in two groups were significantly decreased (P<0.05). After treatment, the levels of CRP, IL-6, and ICAM-1 in the treatment group were lower than those in the control group (P<0.05). Conclusion Lishui Tiaozhi Capsules combined with Rosuvastatin Calcium Tablets is effective in the treatment of hyperlipidemia in children, can regulate apolipoprotein, reduce blood lipid level, and inflammatory reaction, with good safety.

R973

河南省醫(yī)學(xué)科技攻關(guān)計劃項(xiàng)目（2018020856）